PubRank

H-J Kolb

Author PubWeight™ 26.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012 2.78
2 Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005 2.24
3 Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003 1.32
4 Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011 1.24
5 High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2008 1.05
6 Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003 1.05
7 The long-term psychosocial effects of haematopoetic stem cell transplantation. Eur J Cancer Care (Engl) 2003 0.94
8 Cerebral angiitis in four patients with chronic GVHD. Bone Marrow Transplant 2009 0.92
9 Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2008 0.91
10 Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia 2003 0.89
11 Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 2005 0.86
12 Etiology of acute myeloid leukemia following intensive therapy for AML--relapse, secondary disease or bad luck? Leukemia 2002 0.85
13 Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant 2006 0.84
14 ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003 0.84
15 High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis. Leukemia 2006 0.84
16 Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study. Bone Marrow Transplant 2011 0.83
17 Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 2004 0.83
18 Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy. Br J Cancer 2004 0.82
19 Adoption of long-term cultures to evaluate the cryoprotective potential of trehalose for freezing hematopoietic stem cells. Bone Marrow Transplant 2004 0.82
20 Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003 0.79
21 Canine embryonic stem cells: state of the art. Theriogenology 2009 0.79
22 The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant 2002 0.77
23 Minor histocompatibility antigen UTY as target for graft-versus-leukemia and graft-versus-haematopoiesis in the canine model. Scand J Immunol 2013 0.77
24 OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplant 2005 0.77
25 Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005 0.77
26 [Neuromuscular complications after allogeneic bone marrow transplantation]. Nervenarzt 2003 0.76
27 Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia 2007 0.75
28 The diallelic locus encoding the minor histocompatibility antigen HA-1 is evolutionarily conserved. Tissue Antigens 2006 0.75
29 Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia. Leukemia 2006 0.75
30 Canine stem cell factor augments expression of matrix metalloproteinase-9 by CD34 cells. Cytotherapy 2008 0.75
31 [Dose-reduced conditioning before allogeneic stem cell transplantation: principles, clinical protocols and preliminary results]. Dtsch Med Wochenschr 2002 0.75